1、 Correction:Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer[J].J Immunother Cancer,2020,8(1):e000676corr1. Correction:Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer[J].J Immunother Cancer,2020,8(1):e000676corr1.
2、 TANG N,CHENG C,ZHANG X,et al.TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors[J].JCI Insight,2020,5(4):133977. TANG N,CHENG C,ZHANG X,et al.TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors[J].JCI Insight,2020,5(4):133977.
3、 AGLIARDI G,LIUZZI A R,HOTBLACK A,et al.Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma[J].Nat Commun,2021,12(1):444. AGLIARDI G,LIUZZI A R,HOTBLACK A,et al.Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma[J].Nat Commun,2021,12(1):444.
4、 GARCIA-GUERRERO E,RODRIGUEZ-LOBATO L G,SIERRO-MARTINEZ B,et al.All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells[J].Haematologica,2023,108(2):568-580. GARCIA-GUERRERO E,RODRIGUEZ-LOBATO L G,SIERRO-MARTINEZ B,et al.All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells[J].Haematologica,2023,108(2):568-580.
5、 LONG A H,HIGHFILL S L,CUI Y,et al.Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas[J].Cancer Immunol Res,2016,4(10):869-880. LONG A H,HIGHFILL S L,CUI Y,et al.Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas[J].Cancer Immunol Res,2016,4(10):869-880.
6、 WANG H,KAUR G,SANKIN A I,et al.Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies[J].J Hematol Oncol,2019,12(1):59. WANG H,KAUR G,SANKIN A I,et al.Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies[J].J Hematol Oncol,2019,12(1):59.
7、 MCGOWAN E,LIN Q,MA G,et al.PD-1 disrupted CAR-T cells in the treatment of solid tumors:Promises and challenges[J].Biomed Pharmacother,2020(121):109625. MCGOWAN E,LIN Q,MA G,et al.PD-1 disrupted CAR-T cells in the treatment of solid tumors:Promises and challenges[J].Biomed Pharmacother,2020(121):109625.
8、 SONG W,ZHANG M.Use of CAR-T cell therapy,PD-1 blockade,and their combination for the treatment of hematological malignancies[J].Clin Immunol,2020(214):108382. SONG W,ZHANG M.Use of CAR-T cell therapy,PD-1 blockade,and their combination for the treatment of hematological malignancies[J].Clin Immunol,2020(214):108382.
9、 CARUANA I,SAVOLDO B,HOYOS V,et al.Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes[J].Nat Med,2015,21(5):524-529. CARUANA I,SAVOLDO B,HOYOS V,et al.Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes[J].Nat Med,2015,21(5):524-529.
10、 BERNFIELD M,GOTTE M,PARK P W,et al.Functions of cell surface heparan sulfate proteoglycans[J].Annu Rev Biochem,1999(68):729-777. BERNFIELD M,GOTTE M,PARK P W,et al.Functions of cell surface heparan sulfate proteoglycans[J].Annu Rev Biochem,1999(68):729-777.
11、 ZHANG B L,QIN D Y,MO Z M,et al.Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors[J].Sci China Life Sci,2016,59(4):340-348. ZHANG B L,QIN D Y,MO Z M,et al.Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors[J].Sci China Life Sci,2016,59(4):340-348.
12、 PAPA S,van SCHALKWYK M,MAHER J.Clinical evaluation of ErbB-targeted CAR T-Cells,following intracavity delivery in patients with ErbB-expressing solid tumors[J].Methods Mol Biol,2015(1317):365-382. PAPA S,van SCHALKWYK M,MAHER J.Clinical evaluation of ErbB-targeted CAR T-Cells,following intracavity delivery in patients with ErbB-expressing solid tumors[J].Methods Mol Biol,2015(1317):365-382.
13、 van SCHALKWYK M C,PAPA S E,JEANNON J P,et al.Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer[J].Hum Gene Ther Clin Dev,2013,24(3):134-142. van SCHALKWYK M C,PAPA S E,JEANNON J P,et al.Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer[J].Hum Gene Ther Clin Dev,2013,24(3):134-142.
14、 JIN L,TAO H,KARACHI A,et al.CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors[J].Nat Commun,2019,10(1):4016. JIN L,TAO H,KARACHI A,et al.CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors[J].Nat Commun,2019,10(1):4016.
15、 KAKARLA S,CHOW K K,MATA M,et al.Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma[J].Mol Ther,2013,21(8):1611-1620. KAKARLA S,CHOW K K,MATA M,et al.Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma[J].Mol Ther,2013,21(8):1611-1620.
16、 HEGDE M,CORDER A,CHOW K K,et al.Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma[J].Mol Ther,2013,21(11):2087-2101. HEGDE M,CORDER A,CHOW K K,et al.Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma[J].Mol Ther,2013,21(11):2087-2101.
17、 KATSAROU A,SJOSTRAND M,NAIK J,et al.Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence[J].Sci Transl Med,2021,13(623):eabh1962. KATSAROU A,SJOSTRAND M,NAIK J,et al.Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence[J].Sci Transl Med,2021,13(623):eabh1962.
18、 ZHANG M,CHEN D,FU X,et al.Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma[J].Clin Cancer Res,2022,28(13):2830-2843. ZHANG M,CHEN D,FU X,et al.Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma[J].Clin Cancer Res,2022,28(13):2830-2843.
19、 LIANG Z,DONG J,YANG N,et al.Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer[J].Int J Biol Sci,2021,17(15):4365-4376. LIANG Z,DONG J,YANG N,et al.Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer[J].Int J Biol Sci,2021,17(15):4365-4376.
20、 HEGDE M,MUKHERJEE M,GRADA Z,et al.Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape[J].J Clin Invest,2016,126(8):3036-3052. HEGDE M,MUKHERJEE M,GRADA Z,et al.Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape[J].J Clin Invest,2016,126(8):3036-3052.
21、 WU L,ZHANG X H.Tumor-Associated Neutrophils and Macrophages-Heterogenous but Not Chaotic[J].Front Immunol,2020(11):553967. WU L,ZHANG X H.Tumor-Associated Neutrophils and Macrophages-Heterogenous but Not Chaotic[J].Front Immunol,2020(11):553967.
22、 SHAN T,CHEN S,CHEN X,et al.M2-TAM subsets altered by lactic acid promote T-cell apoptosis through the PD-L1/PD-1 pathway[J].Oncol Rep,2020,44(5):1885-1894. SHAN T,CHEN S,CHEN X,et al.M2-TAM subsets altered by lactic acid promote T-cell apoptosis through the PD-L1/PD-1 pathway[J].Oncol Rep,2020,44(5):1885-1894.
23、 WANG X,WANG L,MO Q,et al.Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients[J].Int J Clin Exp Pathol,2015,8(5):5702-5708. WANG X,WANG L,MO Q,et al.Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients[J].Int J Clin Exp Pathol,2015,8(5):5702-5708.
24、 HU D,LI Z,ZHENG B,et al.Cancer-associated fibroblasts in breast cancer:Challenges and opportunities[J].Cancer Commun(Lond),2022,42(5):401-434. HU D,LI Z,ZHENG B,et al.Cancer-associated fibroblasts in breast cancer:Challenges and opportunities[J].Cancer Commun(Lond),2022,42(5):401-434.
25、 OYA Y,HAYAKAWA Y,KOIKE K.Tumor microenvironment in gastric cancers[J].Cancer Sci,2020,111(8):2696-2707. OYA Y,HAYAKAWA Y,KOIKE K.Tumor microenvironment in gastric cancers[J].Cancer Sci,2020,111(8):2696-2707.
26、 CHEN Y,MCANDREWS K M,KALLURI R.Clinical and therapeutic relevance of cancer-associated fibroblasts[J].Nat Rev Clin Oncol,2021,18(12):792-804. CHEN Y,MCANDREWS K M,KALLURI R.Clinical and therapeutic relevance of cancer-associated fibroblasts[J].Nat Rev Clin Oncol,2021,18(12):792-804.
27、 WERB Z,LU P.The role of stroma in tumor development[J].Cancer J,2015,21(4):250-253. WERB Z,LU P.The role of stroma in tumor development[J].Cancer J,2015,21(4):250-253.
28、 PIETROBON V,TODD L A,GOSWAMI A,et al.Improving CAR T-Cell Persistence[J].Int J Mol Sci,2021,22(19):10828. PIETROBON V,TODD L A,GOSWAMI A,et al.Improving CAR T-Cell Persistence[J].Int J Mol Sci,2021,22(19):10828.
29、 JIANG W,HE Y,HE W,et al.Exhausted CD8+T Cells in the tumor immune microenvironment:New pathways to therapy[J].Front Immunol,2020(11):622509. JIANG W,HE Y,HE W,et al.Exhausted CD8+T Cells in the tumor immune microenvironment:New pathways to therapy[J].Front Immunol,2020(11):622509.
30、 PARK J,HSUEH P C,LI Z,et al.Microenvironment-driven metabolic adaptations guiding CD8(+)T cell anti-tumor immunity[J].Immunity,2023,56(1):32-42. PARK J,HSUEH P C,LI Z,et al.Microenvironment-driven metabolic adaptations guiding CD8(+)T cell anti-tumor immunity[J].Immunity,2023,56(1):32-42.
31、 PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264. PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
32、 NISSEN N I,KARSDAL M,WILLUMSEN N.Collagens and cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology[J].J Exp Clin Cancer Res,2019,38(1):115. NISSEN N I,KARSDAL M,WILLUMSEN N.Collagens and cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology[J].J Exp Clin Cancer Res,2019,38(1):115.
33、 HENKE E,NANDIGAMA R,ERGUN S.Extracellular matrix in the tumor microenvironment and its impact on cancer therapy[J].Front Mol Biosci,2020(6):160. HENKE E,NANDIGAMA R,ERGUN S.Extracellular matrix in the tumor microenvironment and its impact on cancer therapy[J].Front Mol Biosci,2020(6):160.
34、 BUCKANOVICH R J,FACCIABENE A,KIM S,et al.Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy[J].Nat Med,2008,14(1):28-36. BUCKANOVICH R J,FACCIABENE A,KIM S,et al.Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy[J].Nat Med,2008,14(1):28-36.
35、 GEORGANAKI M,RAMACHANDRAN M,TUIT S,et al.Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy[J].Oncoimmunology,2020,9(1):1730538. GEORGANAKI M,RAMACHANDRAN M,TUIT S,et al.Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy[J].Oncoimmunology,2020,9(1):1730538.
36、 VEDVYAS Y,MCCLOSKEY J E,YANG Y,et al.Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy[J].Sci Rep,2019,9(1):10634. VEDVYAS Y,MCCLOSKEY J E,YANG Y,et al.Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy[J].Sci Rep,2019,9(1):10634.
37、 MARTINEZ M,MOON E K.CAR T Cells for Solid Tumors:New Strategies for finding,infiltrating,and surviving in the tumor microenvironment[J].Front Immunol,2019(10):128. MARTINEZ M,MOON E K.CAR T Cells for Solid Tumors:New Strategies for finding,infiltrating,and surviving in the tumor microenvironment[J].Front Immunol,2019(10):128.
38、 LEE J,SONG K H,KIM T,et al.Endothelial cell focal adhesion regulates transendothelial migration and subendothelial crawling of T cells[J].Front Immunol,2018(9):48. LEE J,SONG K H,KIM T,et al.Endothelial cell focal adhesion regulates transendothelial migration and subendothelial crawling of T cells[J].Front Immunol,2018(9):48.
39、 ZHOU F,ZHANG F,ZARNITSYNA V I,et al.The kinetics of E-selectin-and P-selectin-induced intermediate activation of integrin αLβ2 on neutrophils[J].J Cell Sci,2021,134(18):jcs258046. ZHOU F,ZHANG F,ZARNITSYNA V I,et al.The kinetics of E-selectin-and P-selectin-induced intermediate activation of integrin αLβ2 on neutrophils[J].J Cell Sci,2021,134(18):jcs258046.
40、 ARNOLD S,KORTLAND J,MALTSEVA D V,et al.Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules,promotes pulmonary metastasis,and reduces survival in a spontaneous xenograft model of human breast cancer[J].J Cancer Res Clin Oncol,2022,148(6):1525-1542. ARNOLD S,KORTLAND J,MALTSEVA D V,et al.Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules,promotes pulmonary metastasis,and reduces survival in a spontaneous xenograft model of human breast cancer[J].J Cancer Res Clin Oncol,2022,148(6):1525-1542.
41、 GENDUSO S,FREYTAG V,SCHETLER D,et al.Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo[J].J Hematol Oncol,2023,16(1):23. GENDUSO S,FREYTAG V,SCHETLER D,et al.Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo[J].J Hematol Oncol,2023,16(1):23.
42、 FRY T J,SHAH N N,ORENTAS R J,et al.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy[J].Nat Med,2018,24(1):20-28. FRY T J,SHAH N N,ORENTAS R J,et al.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy[J].Nat Med,2018,24(1):20-28.
43、 ANURATHAPAN U,CHAN R C,HINDI H F,et al.Kinetics of tumor destruction by chimeric antigen receptor-modified T cells[J].Mol Ther,2014,22(3):623-633. ANURATHAPAN U,CHAN R C,HINDI H F,et al.Kinetics of tumor destruction by chimeric antigen receptor-modified T cells[J].Mol Ther,2014,22(3):623-633.
44、 GARDNER R A,FINNEY O,ANNESLEY C,et al.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults[J].Blood,2017,129(25):3322-3331. GARDNER R A,FINNEY O,ANNESLEY C,et al.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults[J].Blood,2017,129(25):3322-3331.
45、 RAMAKRISHNA S,HIGHFILL S L,WALSH Z,et al.Modulation of target antigen density improves CAR T-cell functionality and persistence[J].Clin Cancer Res,2019,25(17):5329-5341. RAMAKRISHNA S,HIGHFILL S L,WALSH Z,et al.Modulation of target antigen density improves CAR T-cell functionality and persistence[J].Clin Cancer Res,2019,25(17):5329-5341.
46、 CHABANNON C,BONINI C.Structure of and Signalling Through Chimeric Antigen Receptor[M].Cham(CH):Springer,2022:3-5. CHABANNON C,BONINI C.Structure of and Signalling Through Chimeric Antigen Receptor[M].Cham(CH):Springer,2022:3-5.
47、 WAGNER S,MULLINS C S,LINNEBACHER M.Colorectal cancer vaccines:Tumor-associated antigens vs neoantigens[J].World J Gastroenterol,2018,24(48):5418-5432. WAGNER S,MULLINS C S,LINNEBACHER M.Colorectal cancer vaccines:Tumor-associated antigens vs neoantigens[J].World J Gastroenterol,2018,24(48):5418-5432.
48、 ADUSUMILLI P S,ZAUDERER M G,RIVIERE I,et al.A Phase I Trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease,in combination with the Anti-PD-1 agent pembrolizumab[J].Cancer Discov,2021,11(11):2748-2763. ADUSUMILLI P S,ZAUDERER M G,RIVIERE I,et al.A Phase I Trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease,in combination with the Anti-PD-1 agent pembrolizumab[J].Cancer Discov,2021,11(11):2748-2763.
49、 KLAMPATSA A,DIMOU V,ALBELDA S M.Mesothelin-targeted CAR-T cell therapy for solid tumors[J].Expert Opin Biol Ther,2021,21(4):473-486. KLAMPATSA A,DIMOU V,ALBELDA S M.Mesothelin-targeted CAR-T cell therapy for solid tumors[J].Expert Opin Biol Ther,2021,21(4):473-486.
50、 PANG N,SHI J,QIN L,et al.IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin[J].J Hematol Oncol,2021,14(1):118. PANG N,SHI J,QIN L,et al.IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin[J].J Hematol Oncol,2021,14(1):118.
51、 ORDONEZ N G.Application of mesothelin immunostaining in tumor diagnosis[J].Am J Surg Pathol,2003,27(11):1418-1428. ORDONEZ N G.Application of mesothelin immunostaining in tumor diagnosis[J].Am J Surg Pathol,2003,27(11):1418-1428.
52、 BROWN C E,RODRIGUEZ A,PALMER J,et al.Off-the-shelf,steroid-resistant,IL13Rα2-specific CAR T cells for treatment of glioblastoma[J].Neuro Oncol,2022,24(8):1318-1330. BROWN C E,RODRIGUEZ A,PALMER J,et al.Off-the-shelf,steroid-resistant,IL13Rα2-specific CAR T cells for treatment of glioblastoma[J].Neuro Oncol,2022,24(8):1318-1330.
53、 BROWN C E,BADIE B,BARISH M E,et al.Bioactivity and safety of IL13Rα2-Redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma[J].Clin Cancer Res,2015,21(18):4062-4072. BROWN C E,BADIE B,BARISH M E,et al.Bioactivity and safety of IL13Rα2-Redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma[J].Clin Cancer Res,2015,21(18):4062-4072.
54、 BROWN C E,WARDEN C D,STARR R,et al.Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis[J].PLoS One,2013,8(10):e77769. BROWN C E,WARDEN C D,STARR R,et al.Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis[J].PLoS One,2013,8(10):e77769.
55、 GUO Y,FENG K,LIU Y,et al.Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers[J].Clin Cancer Res,2018,24(6):1277-1286. GUO Y,FENG K,LIU Y,et al.Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers[J].Clin Cancer Res,2018,24(6):1277-1286.
56、 ZHANG Y,ZHANG Z,DING Y,et al.Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients[J].J Cancer Res Clin Oncol,2021,147(12):3725-3734. ZHANG Y,ZHANG Z,DING Y,et al.Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients[J].J Cancer Res Clin Oncol,2021,147(12):3725-3734.
57、 O’ROURKE D M,NASRALLAH M P,DESAI A,et al.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J].Sci Transl Med,2017,9(399):eaaa0984. O’ROURKE D M,NASRALLAH M P,DESAI A,et al.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J].Sci Transl Med,2017,9(399):eaaa0984.
58、 NASIRI F,KAZEMI M,MIRAREFIN S,et al.CAR-T cell therapy in triple-negative breast cancer:Hunting the invisible devil[J].Front Immunol,2022(13):1018786. NASIRI F,KAZEMI M,MIRAREFIN S,et al.CAR-T cell therapy in triple-negative breast cancer:Hunting the invisible devil[J].Front Immunol,2022(13):1018786.
59、 KAGOYA Y,TANAKA S,GUO T,et al.A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects[J].Nat Med,2018,24(3):352-359. KAGOYA Y,TANAKA S,GUO T,et al.A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects[J].Nat Med,2018,24(3):352-359.
60、 CHMIELEWSKI M,ABKEN H.TRUCKs:the fourth generation of CARs[J].Expert Opin Biol Ther,2015,15(8):1145-1154. CHMIELEWSKI M,ABKEN H.TRUCKs:the fourth generation of CARs[J].Expert Opin Biol Ther,2015,15(8):1145-1154.
61、 MORGAN R A,YANG J C,KITANO M,et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J].Mol Ther,2010,18(4):843-851. MORGAN R A,YANG J C,KITANO M,et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J].Mol Ther,2010,18(4):843-851.
62、 TILL B G,JENSEN M C,WANG J,et al.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains:pilot clinical trial results[J].Blood,2012,119(17):3940-3950. TILL B G,JENSEN M C,WANG J,et al.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains:pilot clinical trial results[J].Blood,2012,119(17):3940-3950.
63、 LENSCHOW D J,WALUNAS T L,BLUESTONE J A.CD28/B7 system of T cell costimulation[J].Annu Rev Immunol,1996(14):233-258. LENSCHOW D J,WALUNAS T L,BLUESTONE J A.CD28/B7 system of T cell costimulation[J].Annu Rev Immunol,1996(14):233-258.
64、 HARDING F A,MCARTHUR J G,GROSS J A,et al.CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones[J].Nature,1992,356(6370):607-609. HARDING F A,MCARTHUR J G,GROSS J A,et al.CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones[J].Nature,1992,356(6370):607-609.
65、 HUANG S,WANG X,WANG Y,et al.Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies[J].Mol Cancer,2023,22(1):80. HUANG S,WANG X,WANG Y,et al.Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies[J].Mol Cancer,2023,22(1):80.
66、 RAMOS C A,DOTTI G.Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J].Expert Opin Biol Ther,2011,11(7):855-873. RAMOS C A,DOTTI G.Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J].Expert Opin Biol Ther,2011,11(7):855-873.
67、 SADELAIN M,RIVIERE I,BRENTJENS R.Targeting tumours with genetically enhanced T lymphocytes[J].Nat Rev Cancer,2003,3(1):35-45. SADELAIN M,RIVIERE I,BRENTJENS R.Targeting tumours with genetically enhanced T lymphocytes[J].Nat Rev Cancer,2003,3(1):35-45.
68、 TILL B G,JENSEN M C,WANG J,et al.Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells[J].Blood,2008,112(6):2261-2271. TILL B G,JENSEN M C,WANG J,et al.Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells[J].Blood,2008,112(6):2261-2271.
69、 ZHANG W Y,WANG Y,GUO Y L,et al.Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma:an early phase IIa trial report[J].Sig Transduct Target Ther,2016,1:16002. ZHANG W Y,WANG Y,GUO Y L,et al.Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma:an early phase IIa trial report[J].Sig Transduct Target Ther,2016,1:16002.
70、 AHMAD A,UDDIN S,STEINHOFF M.CAR-T cell therapies:An overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-Cell lymphomas[J].Int J Mol Sci,2020,21(11):3906. AHMAD A,UDDIN S,STEINHOFF M.CAR-T cell therapies:An overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-Cell lymphomas[J].Int J Mol Sci,2020,21(11):3906.
71、 AHMAD A.CAR-T Cell Therapy[J].Int J Mol Sci,2020,21(12):4303. AHMAD A.CAR-T Cell Therapy[J].Int J Mol Sci,2020,21(12):4303.
72、 HE W,LI Q,LU Y,et al.Cancer treatment evolution from traditional methods to stem cells and gene therapy[J].Curr Gene Ther,2022,22(5):368-385. HE W,LI Q,LU Y,et al.Cancer treatment evolution from traditional methods to stem cells and gene therapy[J].Curr Gene Ther,2022,22(5):368-385.
